|
Synonyms: JNJ-64007957 | teclistamab-cqyv | Tecvayli®
teclistamab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Teclistamab (JNJ-64007957) is a bispecific IgG4 monoclonal antibody that simultaneously engages CD3 on the surface of T cells, and B-cell maturation antigen (BCMA) that is expressed on the surface of multiple myeloma (MM) cells, to induce a T cell-mediated cytotoxic immune response against the BCMA +ve cells [2].
|
| No information available. |
Summary of Clinical Use  |
| Teclistamab was approved by the EMA in August 2022, and FDA approval followed in October of the same year [3]. Under these authorisations teclistamab can be used as a treatment for multiple myeloma that has relapsed or is refactory to 3 different classes of existing treatments (immunomodulatory drugs, proteasome inhibitors, and an anti-CD38 antibody) [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04557098 | A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 Interventional | Janssen Research & Development, LLC | 1 | |
| NCT03145181 | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 Interventional | Janssen Research & Development, LLC | 1 | |
